Courage Therapeutics Appoints Biopharma Leader Giovanni Ferrara as CEO
“Giovanni is a pivotal hire that frees the rest of us up to focus on advancing our drugs into the clinic as soon as possible,” said Cone. “With our new leadership – including a fully operational new Board – and essential infrastructure in place, we are able to focus on generating meaningful data and fostering service provider relationships.”
The company is raising a second seed financing tranche to further accelerate its development and scaling in partnership with Arsenal Bridge Ventures.
Announcing Courage has received a $7.8M seed investment round to progress our obesity and anorexia programs
The investment will enable Courage Therapeutics to complete essential testing and development to advance its drug candidates to clinical trials. The company’s two drug-development programs aim to address obesity and restrictive eating disorders, such as anorexia nervosa and cachexia, by targeting neural circuits in the brain known as the central melanocortin system.